A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Phase: PHASE2
Conditions: Breast Cancer
Sponsor: Hoffmann-La Roche

Official Title: 
A Multistage, Phase II Study Evaluating the Safety and Efficacy 
of Cobimetinlb plus Paclitaxel, Coblmetlnib plus Atezolizumab 
plus Paclitaxel, or Cobimetinib plus Atezolizumab plus Nab­
Paclitaxel as First-Line Treatment for Patients with Metastatic 
Triple-Negative Breast Cancer 
NCT Number: 
NCT02322814 
Document Date: Protocol Version 8:  25-Oct-2018